Preparation of Novel PARP1 Inhibitors and Their Use in Cancer Treatment

  • ACS Med Chem Lett. 2025 Jul 23;16(8):1494-1496. doi: 10.1021/acsmedchemlett.5c00411.
Xin Zhou  1 ,  Steven H Liang  1
Affiliations
  • 1. Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
PMID: 40832518 DOI: 10.1021/acsmedchemlett.5c00411
Abstract

Poly-(ADP-ribose) polymerase 1 (PARP1) is the most widely studied PARP enzyme, which plays a significant role in DNA damage repair. PARP1 inhibition has emerged as a clinically validated strategy to selectively target two Cancer subtypes: tumors with homologous recombination deficiency (HRD) and Epstein-Barr virus (EBV)-associated malignancies. This patent highlights the synthesis and pharmaceutical compositions of PARP1 inhibitors and their uses in the treatment of Cancer.

Products